PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 42):
The antibody of  claim 1 , wherein:\n (i) the antibody comprises the following six CDRs:\n (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 5; \n (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 6; \n (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 7; \n (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 8; \n (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 9; and \n (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 10; and \n optionally the antibody comprises a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 3 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 4, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 5-7, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 8-10; or optionally the antibody comprises a V H  region comprising the amino acid sequence of SEQ ID NO: 3 and a V L  region comprising the amino acid sequence of SEQ ID NO: 4; or optionally the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 1 and a light chain comprising the amino acid sequence of SEQ ID NO: 2; or (ii) the antibody comprises the following six CDRs:\n (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 25; \n (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 26; \n (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 27; \n (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 28; \n (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 29; and \n (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 30; and \n optionally the antibody comprises a V H  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 23 and a V L  region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 24, wherein the V H  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 25-27, and the V L  region comprises three CDRs comprising the amino acid sequences of SEQ ID NOs: 28-30; or optionally the antibody comprises a V H  region comprising the amino acid sequence of SEQ ID NO: 23 and a V L  region comprising the amino acid sequence of SEQ ID NO: 24; or optionally the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 21 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7431578280726099
- 35 USC 102 Novelty (BERT): 0.5352531973329143
- Combined Prediction Score: 0.7223673649986404
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 251.7619302702428

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test